Compare Adaptive Biotechnologies Corp (ADPT) vs First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $53.21. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals.
| ADPT | QCLN | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Sector/Thematic |
52-Week High | $25.45 | $68.47 |
52-Week Low | $12.30 | $36.11 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
QCLN trades at $53.17, up 2.15% today, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights clean energy ETF growth driven by data center demand and geopolitical shifts, though regulatory hurdles and supply chain costs pose challenges. The stock lacks disclosed financial ratios, requiring deeper fundamental review.
Outlook is cautiously optimistic given sector tailwinds, but investment hinges on policy stability and cost management. Risks include U.S. permit delays and Chinese trade tensions, while institutional sentiment appears mixed amid volatile clean energy markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →
